New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTFRX, WETF, HK, AWI, PFE, CRM, ZNGA, ORLY, OIS, OPEN, NLSN, MRK, ANGI, CBT, CVX, DVN, DRE, FRC, GPS, GILD, AGNOn the Fly: Analyst Upgrade Summary
Allergan (AGN) upgraded to Buy from Neutral at Citigroup... Angie's List (ANGI) upgraded to Outperform from Market Perform at Barrington... Cabot (CBT) upgraded to Buy from Neutral at SunTrust... Chevron (CVX) upgraded to Strong Buy from Outperform at Raymond James... Devon Energy (DVN) upgraded to Outperform from Neutral at Credit Suisse... Duke Realty (DRE) upgraded to Outperform from Sector Perform at RBC Capital... First Republic (FRC) upgraded to Outperform from Market Perform at Keefe Bruyette,,, Gap (GPS) upgraded to Buy from Neutral at UBS... Gilead (GILD) upgraded to Outperform from Neutral at RW Baird... Merck (MRK) upgraded to Buy from Neutral at SunTrust... Nielsen (NLSN) upgraded to Buy from Hold at Pivotal Research... OpenTable (OPEN) upgraded to Neutral from Sell at Citigroup... Pfizer (PFE) upgraded to Buy from Hold at Jefferies... Salesforce.com (CRM) upgraded to Buy from Neutral at Roth Capital... Zynga (ZNGA) upgraded to Buy from Neutral at UBS... O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast... Oil States (OIS) upgraded to Buy from Accumulate at Tudor Pickering... Armstrong World (AWI) upgraded to Buy from Hold at Gabelli... Halcon Resources (HK) upgraded to Neutral from Reduce at Global Hunter... Wisdom Tree (WETF) upgraded to Buy from Neutral at BofA/Merrill... Forest Labs (FRX) upgraded to Overweight from Neutral at JPMorgan.
News For AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX From The Last 14 Days
Check below for free stories on AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 11, 2014
09:48 EDTGILDSenators make new request to Gilead for Sovaldi pricing details
Senate Finance Committee Chairman Ron Wyden and senior Finance Committee member Chuck Grassley made public their request for detailed pricing information on Gilead's Sovaldi, a Hepatitis C virus drug. Wyden and Grassley have asked Gilead Sciences for information about Sovaldi, a drug developed to treat and cure HCV, they disclosed, stating, “Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug." Reference Link
09:37 EDTCRMSalesforce.com agrees to acquire RelateIQ
Subscribe for More Information
09:09 EDTGPSOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTGILDAmerican Enterprise Institute holds a discussion
Discussion entitled, "How Will We Pay for Cost of Cures" focuses on improving the development of transformative medicines and developing financing mechanisms to pay for them and is being held in Washington, D.C. on July 11 at 8 am. Webcast Link
07:36 EDTGILDJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
July 10, 2014
18:35 EDTGPSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Joe's Jeans (JOEZ), up 15.5% after reporting second quarter results above analyst estimates... Barracuda Networks (CUDA), up 2.2% after reporting quarterly results and guidance... DOWN AFTER EARNINGS: PriceSmart (PSMT), down 3.7% after reporting third quarter revenue below analyst estimates... Rent-A-Center (RCII), down 11% after reporting disappointing preliminary second quarter results. ALSO LOWER: Gap (GPS), down 2% after reporting June Same Store Sales down 2%... Arotech (ARTX), down 5.6% after filing an automatic common stock shelf... NOTABLE: MGIC Investment (MTG), down 4.8% and Radian Group (RDN), down 3.8% following the FHFA proposal to tighten capital rules for mortgage insurers.
17:08 EDTCVXChevron reports Q2-May U.S. upstram production 665 MBOED vs. 659 MBOED in 2Q13
Subscribe for More Information
17:05 EDTCVXChevron sees Q2 earnings higher than Q1
Subscribe for More Information
16:12 EDTMRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
16:03 EDTGPSGap reports June net sales up 1%, SSS down 2%
Subscribe for More Information
July 9, 2014
18:50 EDTZNGAOn The Fly: After Hours Movers
Subscribe for More Information
18:31 EDTAGNShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTAGNAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
16:13 EDTZNGAZynga appoints Google executive Dugan to board
Subscribe for More Information
16:01 EDTGILDOptions Update; July 9, 2014
Subscribe for More Information
09:01 EDTDVNDevon Energy management to meet with Oppenheimer
Meeting to be held in Canada on July 16 hosted by Oppenheimer.
09:00 EDTDVNDevon Energy management to meet with Oppenheimer
Subscribe for More Information
07:33 EDTGILDGilead on track to post Q2 revenue beat, says RBC Capital
Subscribe for More Information
06:49 EDTPFEPfizer given dismissal of U.S. investor class action before trial, Reuters says
Subscribe for More Information
06:19 EDTAGNAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackman’s hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use